Treatment of Limited Cutaneous Systemic Sclerosis with Musculoskeletal Involvement
When limited cutaneous systemic sclerosis (lcSSc) presents with musculoskeletal involvement, targeted pharmacological management is indicated. The presence of musculoskeletal features shapes the treatment selection for this patient population.
Clinical scenario
Limited cutaneous systemic sclerosis in the setting of musculoskeletal involvement — a combination that directs specific evidence-based treatment decisions beyond general scleroderma management.
Treatment approach
Evidence supports the use of a disease-modifying agent in this scenario — Methotrexate is among the therapies considered for addressing musculoskeletal involvement in this condition. The complete selection criteria, monitoring requirements, and full regimen detail are available in the structured protocol.
References
DOI: 10.1136/ard-2024-226430
Methotrexate should be considered for the treatment of musculoskeletal involvement in SSc.
View source ↗